Bill Sponsor
Senate Bill 476
116th Congress(2019-2020)
Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
Introduced
Introduced
Introduced in Senate on Feb 13, 2019
Overview
Text
Sponsor
Introduced
Feb 13, 2019
Latest Action
Feb 13, 2019
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
476
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Democrat
Oregon
Democrat
Delaware
Democrat
Delaware
Democrat
Massachusetts
Democrat
Montana
Senate Votes (0)
House Votes (0)
No Senate votes have been held for this bill.
Summary

Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019

This bill establishes a series of requirements relating to drug rebates and discounts under Medicare and Medicare Advantage (MA).

Specifically, for each pharmacy benefits manager (PBM) that contracts with a prescription drug plan (PDP) under Medicare or MA, or with a qualified health benefits plan offered through a health insurance exchange, HHS must publish on its website (1) the amount and type of rebates and discounts negotiated by the PBM and the extent to which these rebates and discounts are passed on to the plan sponsor, and (2) the difference between the amount paid by the plan sponsor to the PBM and the amount paid by the PBM to pharmacies.

As a condition of participation as a contractor under Medicare or MA, a PBM must pass on to a PDP sponsor a minimum percentage, as established by HHS, of the amount of rebates and discounts negotiated by the PBM that are attributable to patient utilization under the plan.

The bill also modifies requirements regarding Medicare enrollees' access to negotiated drug prices. Current law requires a PDP sponsor to provide enrollees in Medicare or MA with access to negotiated drug prices that account for rebates and discounts. The bill requires that, with respect to a covered drug, a negotiated price (or, if necessary, an approximate negotiated price) be provided at the point of sale.

Text (1)
February 13, 2019
Actions (2)
02/13/2019
Read twice and referred to the Committee on Finance.
02/13/2019
Introduced in Senate
Public Record
Record Updated
Nov 1, 2022 4:17:45 PM